Company Monitoring Page for Astellas

latest headlines for company on cafepharma

Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Fierce Pharma
Thu, 01/23/20 - 12:12 pm
Tags:
Amgen, Astellas, Japan, BeiGene, China
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
BioSpace
Tue, 01/14/20 - 10:46 am
Tags:
Adaptimmune, SPEAR-T, Astellas, CAR-T, cell therapy, drug development
A big finish confirms 2019 as a takeover year to remember
EP Vantage
Thu, 01/9/20 - 10:49 am
Tags:
M&A, AbbVie, Allergan, Astellas, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Sanofi
Corporate and regulatory developments over the Christmas period
EP Vantage
Thu, 01/2/20 - 11:39 pm
Tags:
Astellas, M&A, Qiagen, AstraZeneca, Bausch Health, BeiGene, Celyad, Immunomedics, Merck, Merck KGaA, Ono Pharmaceutical, Pfizer, Pharming, Xyphos Biosciences
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Reuters
Mon, 12/30/19 - 10:59 am
Tags:
Astellas, Xyphos Biosciences, M&A, Audentes Therapeutics
Seattle Genetics, Astellas snag quick FDA approval for bladder cancer-fighter Padcev
Fierce Pharma
Wed, 12/18/19 - 11:57 pm
Tags:
Seattle Genetics, Astellas, FDA, Padcev, metastatic bladder cancer
Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod
Fierce Pharma
Mon, 12/16/19 - 10:37 pm
Tags:
Pfizer, Astellas, Xtandi, prostate cancer, JNJ, Erleada, FDA
Deserted by Astellas and Merck, little Correvio still can't win over FDA panel concerned with its AFib drug's safety
Endpoints
Wed, 12/11/19 - 10:29 am
Tags:
Correvio, Astellas, Merck, clinical trials, atrial fibrillation, Vernakalant, Brinavess
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
Wed, 12/4/19 - 10:02 am
Tags:
gene therapy, Astellas, Audentes Therapeutics, M&A, Novartis, Medicines Company
Japan's Astellas to buy Audentes for $3 billion in gene therapy push
Reuters
Mon, 12/2/19 - 11:58 pm
Tags:
Astellas, M&A, gene therapy, Audentes Therapeutics
Top 10 pharma settlements since 2018
Fierce Pharma
Tue, 11/19/19 - 10:27 am
Tags:
settlements, Reckitt Benckiser, JNJ, Bayer, Allergan, Actelion, Purdue Pharma, Teva Pharmaceutical, Endo, Teikoku, Insys, Pfizer, GSK, Astellas, Amgen
Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators
Pharmaceutical Business Review
Thu, 10/31/19 - 11:03 am
Tags:
Astellas, Pandion Therapeutics, immunomodulators, autoimmune disease, Pancreas
Seattle Genetics makes case it can be more than Adcetris
Biopharma Dive
Mon, 09/30/19 - 12:03 pm
Tags:
Seattle Genetics, Adcetris, clinical trials, ESMO, enfortumab vedotin, Astellas, tucatinib
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Sat, 09/28/19 - 04:36 pm
Tags:
Seattle Genetics, Astellas, enfortumab vedotin, bladder cancer, ESMO, urothelial cancer
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Pharmaforum
Sun, 09/22/19 - 11:02 pm
Tags:
Astellas, AML, Xospata, Europe, Daiichi Sankyo
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Endpoints
Fri, 09/20/19 - 10:40 pm
Tags:
Astellas, FDA, gilteritinib, Europe, AML, Daiichi Sankyo
Astellas hires first chief patient exec to make 'centricity' more than a buzzword
Fierce Pharma
Mon, 09/9/19 - 10:03 am
Tags:
Astellas, patients, patient centricity, Sanofi, drug discovery
Pfizer, Astellas rocket toward broader Xtandi use with FDA 'priority' tag
Fierce Pharma
Thu, 08/22/19 - 11:56 am
Tags:
Pfizer, Astellas, Xtandi, prostate cancer, FDA, priority review
Astellas tests gamification ideas with Japanese universities
Pharmaforum
Thu, 08/15/19 - 10:45 am
Tags:
Astellas, Japan, gamification
Astellas pushes non-hormonal menopause drug into phase 3
Pharmaforum
Wed, 08/7/19 - 11:48 pm
Tags:
Astellas, menopause, clinical trials, fezolinetant

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.